Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03543813 · ClinicalTrials.gov registry record · Phase 1
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
A Phase 1 study, sponsored by CytomX Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT03543813 is a Phase 1 study that has completed, run by CytomX Therapeutics. The registered enrollment target is 133 participants.
The verdict
NCT03543813, a Phase 1 study, has completed, sponsored by CytomX Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). The antitumor activity of CX-2029 will be evaluated in subjects with head and neck squamous cell carcinoma (HNSCC), DLBCL, non-small cell lung cancer (NSCLC) (squamous cell histology only), or esophageal (esophageal adenocarcinoma \[EAC\], esophageal squamous cell carcinoma \[ESCC\], or gastroesophageal \[GE\] junction) cancer. PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc
Interventions
- DRUG CX-2029
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03543813
The ClinicalTrials.gov registry entry for NCT03543813 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytomX Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CX-2029 is the first listed.
NCT03543813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03543813 about?
NCT03543813 is a clinical study titled "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL". The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). Th...
What is the current status of trial NCT03543813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2018-06-15. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT03543813?
The interventions under investigation include: CX-2029 (DRUG).
Who is sponsoring clinical trial NCT03543813?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.